Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-benzylsuccinic acid is the (R)-enantiomer of 2-benzylsuccinic acid, a small molecule dicarboxylic organic compound with the formula C11H12O4 and a molecular weight of approximately 208.21 g/mol[1][4][5]. It is structurally related to succinic acid with a benzyl group at the 2-position. L-benzylsuccinic acid acts as an inhibitor of carboxypeptidase A1 and carboxypeptidase B2 enzymes[2][3], which are involved in protein digestion and various metabolic pathways such as complement and coagulation cascades. It has been used experimentally as a biochemical tool for enzyme inhibition studies but does not have established pharmaceutical indications or approved therapeutic uses. Its mechanism involves competitive inhibition at the active site of target carboxypeptidases[3]. The compound is primarily used in research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-benzylsuccinic acid.